Skip to main content

Telomir Pharmaceuticals, Inc.

TELO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001971532

No open-market purchases or sales by Telomir Pharmaceuticals, Inc. insiders were filed in the last 90 days; 33 institutions reported holding it in 13F filings for Q2 2026, worth $3.80M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Telomir Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Telomir Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Telomir Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Whalen Matthew PrattDirector–Jul 27, 20262
MacPherson Edward CloustonDirector–Jul 27, 20262
Del Giudice Matthew PaulDirector–Jul 27, 20262
Aminov ErezCEO and Chairman7,319,710May 22, 20262
Bay Shore Trust10% Owner1,902,659IndirectNov 25, 20240
Yanez MichelleChief Financial Officer–Sep 4, 20240
Jerman Michael AllenDirector–Aug 29, 20240
McNulty Brian Patrick10% Owner1,902,659IndirectFeb 15, 20240

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 15, 2024 (view filing)4:11 PM ETFeb 132 daysBay Shore Trust and 1 other10% OwnerPPurchase+138.0K$7.00+$966.0K+7.8%1.90M after3 lots